Albireo Pharma, Inc. (ALBO): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALBO POWR Grades
- Sentiment is the dimension where ALBO ranks best; there it ranks ahead of 71.63% of US stocks.
- The strongest trend for ALBO is in Value, which has been heading down over the past 178 days.
- ALBO's current lowest rank is in the Quality metric (where it is better than 5.44% of US stocks).
ALBO Stock Summary
- With a year-over-year growth in debt of 1,024.42%, ALBIREO PHARMA INC's debt growth rate surpasses 98.14% of about US stocks.
- Over the past twelve months, ALBO has reported earnings growth of 311.67%, putting it ahead of 95.21% of US stocks in our set.
- Revenue growth over the past 12 months for ALBIREO PHARMA INC comes in at 432.68%, a number that bests 97.95% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to ALBIREO PHARMA INC, a group of peers worth examining would be NHWK, NVCN, ACAD, SPRO, and KOPN.
- ALBO's SEC filings can be seen here. And to visit ALBIREO PHARMA INC's official web site, go to www.albireopharma.com.
ALBO Valuation Summary
- In comparison to the median Healthcare stock, ALBO's EV/EBIT ratio is 155.56% lower, now standing at -6.
- Over the past 191 months, ALBO's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for ALBO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ALBO | 2023-02-17 | 15.8 | 9.0 | -6.9 | -6.0 |
| ALBO | 2023-02-16 | 15.9 | 9.1 | -7.0 | -6.1 |
| ALBO | 2023-02-15 | 15.9 | 9.1 | -7.0 | -6.1 |
| ALBO | 2023-02-14 | 16.0 | 9.2 | -7.0 | -6.1 |
| ALBO | 2023-02-13 | 15.9 | 9.1 | -7.0 | -6.1 |
| ALBO | 2023-02-10 | 16.0 | 9.2 | -7.0 | -6.1 |
ALBO Growth Metrics
- The 4 year price growth rate now stands at 18.49%.
- The year over year revenue growth rate now stands at 420.86%.
- Its year over year price growth rate is now at -7.12%.
The table below shows ALBO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 57.391 | -115.322 | -131.145 |
| 2022-06-30 | 51.223 | -113.175 | -36.259 |
| 2022-03-31 | 45.445 | -108.252 | -32.731 |
| 2021-12-31 | 40.579 | -107.559 | -34.03 |
| 2021-09-30 | 10.774 | -121.863 | -47.867 |
| 2021-06-30 | 9.241 | -120.352 | -135.696 |
ALBO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ALBO has a Quality Grade of D, ranking ahead of 12.41% of graded US stocks.
- ALBO's asset turnover comes in at 0.035 -- ranking 346th of 680 Pharmaceutical Products stocks.
- LCI, MBIO, and XNCR are the stocks whose asset turnover ratios are most correlated with ALBO.
The table below shows ALBO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.035 | 1 | -72.830 |
| 2021-03-31 | 0.034 | 1 | -28.871 |
| 2020-12-31 | 0.035 | 1 | -35.203 |
| 2020-09-30 | 0.057 | 1 | -49.355 |
| 2020-06-30 | 0.064 | 1 | -125.682 |
| 2020-03-31 | 0.061 | 1 | 30.641 |
ALBO Price Target
For more insight on analysts targets of ALBO, see our ALBO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $75.86 | Average Broker Recommendation | 1.25 (Strong Buy) |
ALBO Stock Price Chart Interactive Chart >
ALBO Price/Volume Stats
| Current price | $44.15 | 52-week high | $45.23 |
| Prev. close | $44.25 | 52-week low | $16.02 |
| Day low | $43.99 | Volume | 1,241,200 |
| Day high | $44.90 | Avg. volume | 704,539 |
| 50-day MA | $37.97 | Dividend yield | N/A |
| 200-day MA | $25.15 | Market Cap | 913.95M |
Albireo Pharma, Inc. (ALBO) Company Bio
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders. The company is based in Boston, Massachusetts.
Latest ALBO News From Around the Web
Below are the latest news stories about ALBIREO PHARMA INC that investors may wish to consider to help them evaluate ALBO as an investment opportunity.
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year. |
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille SyndromeBylvay (odevixibat) granted Priority Review by U.S. FDAASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patientsApproval in second indication would more than double Bylvay market opportunity BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the U.S. Food and Drug |
Why These Two Biotech Stocks Blasted Higher This WeekTwo somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca, while Albireo Pharma (NASDAQ: ALBO) is set to be owned by France-based peer Ipsen. Both of these deals are very lucrative, to the point where CinCor's stock rocketed 146% over the course of the week, and Albireo shot 92% skyward, according to data compiled by S&P Global Market Intelligence. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning! |
ALBO Price Returns
| 1-mo | 1.49% |
| 3-mo | 127.93% |
| 6-mo | 135.72% |
| 1-year | 44.38% |
| 3-year | 150.85% |
| 5-year | 32.38% |
| YTD | 104.30% |
| 2022 | -7.21% |
| 2021 | -37.91% |
| 2020 | 47.56% |
| 2019 | 3.63% |
| 2018 | -4.18% |
Continue Researching ALBO
Want to do more research on Albireo Pharma Inc's stock and its price? Try the links below:Albireo Pharma Inc (ALBO) Stock Price | Nasdaq
Albireo Pharma Inc (ALBO) Stock Quote, History and News - Yahoo Finance
Albireo Pharma Inc (ALBO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...